ClinicalTrials.gg
CompletedNCT01139021Updated Apr 10, 2015Results posted

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

A Phase 3 interventional study of rMenB+OMV NZ in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 19 sites in 2 countries. Open to participants aged 23 Months to 27 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-10.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
508
Allocation
Non-randomized
Ages
23 Months to 27 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
11th of 21
508 · median 508
Started
2010
with 1 other
Phase 3
7 of 21
none open now
Registered
8th of 21
by date
Lead sponsor
10 of 21
Novartis Vaccines

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 8th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 23 Months to 27 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.

03

Conditions studied

  • Meningococcal Disease

Keywords

  • Children
  • Meningococcal disease
  • Prevention
  • Vaccination
04

Who can participate

Ages eligible
23 Months to 27 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female children, 23 to 27 months of age (naïve children)
  • Available for all the visits scheduled in the study;
  • For whom parent(s)/legal guardian(s) have given written according to local regulations after the nature of the study has been explained;
  • Available for all the visits scheduled in the study;
  • In good health as determined by medical history, physical examination, clinical judgment of the investigator.
  • Healthy children who participated in the immunogenicity part of V72P13E1 and have received their last vaccination 12 months (-30/+60 days) before enrolment in V72P13E2;
  • Who received all vaccinations with rMenB+OMV NZ in V72P13 and V72P13E1 according to the protocols;
  • Who provided at least the blood sample one month after their fourth dose of rMenB+OMV NZ (groups B246_12M12/B246_12M13) or after their second dose of rMenB+OMV NZ (groups B13_15_27/B12_14_26) in V72P13E1 according to the protocol;
  • For whom parent(s)/legal guardian(s) had given written informed consent after the nature of the study has been explained;
  • In good health as determined by medical history, physical examination, clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Subjects whose parent(s)/legal guardian(s) were unwilling or unable to give written to participate in the study;
  • History of any meningococcal B vaccine administration;
  • Previous ascertained or suspected disease caused by N. meningitidis;
  • For whom parent(s)/legal guardian(s) have given written informed consent according to local regulations after the nature of the study has been explained;
  • History of severe allergic reaction after previous vaccinations or to any vaccine component;
  • Antibiotics treatment within 6 days prior to enrolment;
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;
  • Any serious chronic or progressive disease
  • Known or suspected impairment/ alteration of the immune system,
  • Receipt of, or intent to immunize with another vaccine, within 30 days prior and after vaccination with the vaccines (within 14 days for licensed flu vaccines)
  • Significant acute or chronic infection within the previous 7 days or axillary temperature ≥38C within the previous day;
  • Family members and household members of research staff;
  • Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, disease, (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS), or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
  • Known or suspected impairment/alteration of the immune system, therapy, use of systemic or chronic use of inhaled high-potency corticosteroids within 30 days prior to enrolment (use of low or moderate doses of inhaled steroids is not an exclusion);
  • Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days prior to enrolment;
  • Participation in another clinical trial within 90 days prior to enrolment or planned for during study;
  • Receipt of, or intent to immunize with any other vaccine(s) within 30 days prior to enrolment (exception: flu-vaccines should not be administered within 14 days prior to enrolment);
  • Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
508 participants (actual)

Study arms

  • Experimental
    B246_12_M12

    Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B246_12M13

    Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B13_15_27

    Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B12_14_26

    Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B_24_26

    Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B12M13

    Subject was randomized in group B13_15_27 but treated as group B12_M13.

    Biological: rMenB+OMV NZ

Interventions

  • BiologicalrMenB+OMV NZ

    Drug page: 4CMenB vaccine

    Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.

    To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).

    Time frame: 12 months post booster (fourth) vaccination.

  2. Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.

    To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on MITT population (Primary).

    Time frame: 12 months post booster (fourth) vaccination.

  3. Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.

    To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953. Analysis was done on MITT population (Primary).

    Time frame: 12 months post booster (fourth) vaccination.

Secondary outcomes

  1. GMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.

    To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.

    Time frame: 12 months post two catch-up dose vaccination and 6 months post booster dose.

  2. Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.

    To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.

    Time frame: 6month post booster dose and 12 months post two catch-up dose vaccination.

  3. Percentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.

    To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.

    Time frame: 1 month post booster dose versus prebooster.

  4. GMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.

    To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.

    Time frame: 12 months post two catch-up dose vaccination and 6 months post booster dose.

  5. GMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

    To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

    Time frame: 1 month and 6 months post two catch-up doses.

  6. Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

    To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

    Time frame: 1 month and 6 months post two catch-up doses.

  7. Percentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

    To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains. Analysis was done on MITT population (Secondary).

    Time frame: 1 month post two catch-up doses versus prevaccination

  8. GMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.

    To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain. Analysis was done on MITT population (Secondary).

    Time frame: 1 month and 6 months post two catch-up doses.

  9. Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.

    To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.

    Time frame: Up to 7 days after any vaccination.

  10. Number of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.

    To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.

    Time frame: Up to 7 days after any vaccination.

  11. Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

    To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

    Time frame: Up to 7 days after any vaccination.

  12. Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

    To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.

    Time frame: Up to 7 days after any vaccination

07

Results

Posted Apr 10, 2015

Participant flow

Participants were enrolled from Finland and Czech Republic study center.

Participant flow — Overall Study
MilestoneB246_12M12B246_12M13B13_15_27B12_14_26B_24_26B12M13
Started15215367191161
Completed15115367181071
Not completed100190
Withdrew: Adverse event000010
Withdrew: Lost to follow-up000020
Withdrew: Protocol violation100020
Withdrew: Withdrawal by subject000140

Outcome measures

PrimaryGeometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.

To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).

Time frame:
12 months post booster (fourth) vaccination.
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.
TitersB246_12M12B246_12M13B246_12Tot
H44/76-SL (N=147,152,299)7.38 (5.55 to 9.83)8.3 (6.17 to 11)6.5 (5.63 to 7.5)
5/99 (N=147,151,298)68 (52 to 91)90 (67 to 121)81 (71 to 94)
NZ98/2541.57 (1.24 to 1.99)1.79 (1.4 to 2.29)1.91 (1.7 to 2.15)
M10713 (N=143,148,291)4.37 (3.24 to 5.9)3.62 (2.65 to 4.94)3.35 (2.88 to 3.9)
PrimaryPercentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.

To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately). Analysis was done on MITT population (Primary).

Time frame:
12 months post booster (fourth) vaccination.
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.
Percentage of subjectsB246_12M12B246_12M13B246_12Tot
H44/76-SL (hSBA ≥1:5) (N=147, 152, 299)60 (51 to 68)64 (56 to 71)62 (56 to 67)
5/99 (hSBA ≥1:5) (N=147, 151, 298)96 (91 to 98)99 (95 to 100)97 (95 to 99)
NZ98/254 (hSBA ≥1:5)18 (12 to 25)17 (11 to 24)17 (13 to 22)
M10713 (hSBA ≥1:5) (N=143, 148, 291)40 (32 to 48)32 (25 to 41)36 (31 to 42)
H44/76-SL (hSBA ≥1:8) (N=147, 152, 299)44 (35 to 52)47 (39 to 55)45 (39 to 51)
5/99 (hSBA ≥1:8) (N=147, 151, 298)96 (91 to 98)98 (94 to 100)97 (94 to 99)
NZ98/254 (hSBA ≥1:8) (N=147, 153, 300)12 (7 to 19)14 (9 to 21)13 (10 to 18)
M10713 (hSBA ≥1:8) (N=143, 148, 291)31 (23 to 39)24 (17 to 31)27 (22 to 33)
PrimaryGeometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.

To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953. Analysis was done on MITT population (Primary).

Time frame:
12 months post booster (fourth) vaccination.
Reported as:
Geometric mean · Concentration IU/mL
Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.
Concentration IU/mLB246_12M12B246_12M13B246_12Tot
Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.360 (293 to 442)389 (314 to 482)352 (317 to 391)
SecondaryGMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.

To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.

Time frame:
12 months post two catch-up dose vaccination and 6 months post booster dose.
Reported as:
Geometric mean · Titers
GMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.
TitersB13_15_27B12_14_26B12+B13Tot
H44/76-SL (12months)14 (9.01 to 23)8.4 (4.13 to 17)10 (8 to 13)
5/99 (12months) (N= 67, 18, 85)73 (43 to 123)71 (32 to 154)65 (49 to 85)
NZ98/254 (12months) (N= 67, 18, 85)1.67 (1.09 to 2.55)1.2 (0.64 to 2.27)1.75 (1.39 to 2.2)
M10713 (12months) (N= 64, 18, 82)3.74 (2.14 to 6.54)3.29 (1.43 to 7.56)3.4 (2.5 to 4.61)
H44/76-SL (6months) (N= 67, 17, 84)68 (41 to 113)70 (32 to 151)51 (38 to 68)
5/99 (6months) (N= 67, 17, 84)524 (332 to 827)525 (263 to 1047)518 (405 to 664)
NZ98/254 (6months) (N= 67, 17, 84)8.87 (5.23 to 15)16 (7.13 to 35)8.8 (6.63 to 12)
M10713 (6months) (N= 66, 16, 82)30 (18 to 49)36 (17 to 78)26 (20 to 33)
SecondaryPercentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.

To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.

Time frame:
6month post booster dose and 12 months post two catch-up dose vaccination.
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.
Percentage of subjectsB13_15_27B12_14_26B12+B13Tot
H44/76-SL (hSBA ≥1:5) (12months)75 (63 to 84)56 (31 to 78)71 (60 to 80)
5/99 (hSBA ≥1:5) (12months) (N= 67, 18, 85)97 (90 to 100)94 (73 to 100)96 (90 to 99)
NZ98/254 (hSBA ≥1:5) (12months) (N= 67, 18, 85)18 (10 to 29)6 (0 to 27)15 (8 to 25)
M10713 (hSBA ≥1:5) (12months) (N= 64, 18, 82)39 (27 to 52)28 (10 to 53)37 (26 to 48)
H44/76-SL (hSBA ≥1:5) (6months) (N= 67, 17, 84)99 (92 to 100)100 (80 to 100)99 (94 to 100)
5/99 (hSBA ≥1:5) (6months) (N= 67, 18, 84)100 (95 to 100)100 (80 to 100)100 (96 to 100)
NZ98/254 (hSBA ≥1:5) (6months) (N= 67, 18, 84)73 (61 to 83)82 (57 to 96)75 (64 to 84)
M10713 (hSBA ≥1:5) (6months) (N= 66, 16, 82)92 (83 to 97)94 (70 to 100)93 (85 to 97)
H44/76-SL (hSBA ≥1:8) (12months) (N= 67, 18, 85)63 (50 to 74)56 (31 to 78)61 (50 to 72)
5/99 (hSBA ≥1:8) (12months) (N= 67, 18, 85)96 (87 to 99)94 (73 to 100)95 (88 to 99)
NZ98/254 (hSBA ≥1:8) (12months) (N= 67, 18, 85)15 (7 to 26)6 (0 to 27)13 (7 to 22)
M10713 (hSBA ≥1:8) (12months) (N= 64, 18, 82)27 (16 to 39)22 (6 to 48)26 (17 to 36)
H44/76-SL (hSBA ≥1:8) (6months) (N=67, 17, 84)91 (82 to 97)100 (80 to 100)93 (85 to 97)
5/99 (hSBA ≥1:8) (6months) (N= 67, 17, 84)100 (95 to 100)94 (71 to 100)99 (94 to 100)
NZ98/254 (hSBA ≥1:8) (6months) (N= 67, 17, 84)52 (40 to 65)65 (38 to 86)55 (44 to 66)
M10713 (hSBA ≥1:8) (6months) (N= 66, 16, 82)86 (76 to 94)81 (54 to 96)85 (76 to 92)
SecondaryPercentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.

To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.

Time frame:
1 month post booster dose versus prebooster.
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.
Percentage of SubjectsB13_15_27B12_14_26B12+B13Tot
H44/76-SL (N= 66, 18, 84)100 (95 to 100)100 (81 to 100)100 (96 to 100)
5/99 (N= 67, 18, 85)99 (92 to 100)100 (81 to 100)99 (94 to 100)
NZ98/254 (N= 65, 18, 83)97 (89 to 100)94 (73 to 100)96 (90 to 99)
M10713 (N= 62, 16, 78)82 (70 to 91)88 (62 to 98)83 (73 to 91)
SecondaryGMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.

To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age. Both the groups received MMRV at 12 months of age.

Time frame:
12 months post two catch-up dose vaccination and 6 months post booster dose.
Reported as:
Geometric mean · Concentration IU/mL
GMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.
Concentration IU/mLB13_15_27B12_14_26B12+B13Tot
287-953 (6months) (N=67, 17, 84)2314 (1596 to 3355)3259 (1859 to 5712)2597 (2104 to 3205)
287-953 (12months)219 (149 to 322)246 (138 to 437)227 (185 to 278)
SecondaryGMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

Time frame:
1 month and 6 months post two catch-up doses.
Reported as:
Geometric mean · Titers
GMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
TitersB_24_26
H44/76-SL (1months) (N= 105)220 (186 to 261)
5/99 (1months) (N= 103)455 (372 to 556)
NZ98/254 (1months) (N=108 )27 (23 to 32)
M10713 (1months) (N=100)38 (32 to 45)
H44/76-SL (6months) (N=104)22 (18 to 27)
5/99 (6months) (N= 104)71 (57 to 89)
NZ98/254 (6 months) (N= 104)1.88 (1.57 to 2.26)
M10713 (6months) (N= 104)8.04 (6.39 to 10)
SecondaryPercentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

Time frame:
1 month and 6 months post two catch-up doses.
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
Percentage of subjectsB_24_26
H44/76-SL (hSBA ≥1:5) (1months) (N=105)100 (97 to 100)
5/99 (hSBA ≥1:5) (1months) (N= 103)99 (95 to 100)
NZ98/254 (hSBA ≥1:5) (1months) (N= 108)98 (93 to 100)
M10713 (hSBA ≥1:5) (1months) (N= 100)97 (91 to 99)
H44/76-SL (hSBA ≥1:5) (6months) (N=104)93 (87 to 97)
5/99 (hSBA ≥1:5) (6months) (N= 104 )96 (90 to 99)
NZ98/254 (hSBA ≥1:5) (6months) (N= 104)18 (11 to 27)
M10713 (hSBA ≥1:5) (6months) (N= 104)70 (60 to 79)
H44/76-SL (hSBA ≥1:8) (1months) (N=105)100 (97 to 100)
5/99 (hSBA ≥1:8) (1months) (N= 103)99 (95 to 100)
NZ98/254 (hSBA ≥1:8) (1months) (N= 108)96 (91 to 99)
M10713 (hSBA ≥1:8) (1months) (N= 100)95 (89 to 98)
H44/76-SL (hSBA ≥1:8) (6months) (N=104)88 (80 to 93)
5/99 (hSBA ≥1:8) (6months) (N= 104)96 (90 to 99)
NZ98/254 (hSBA ≥1:8) (6months) (N= 104)12 (6 to 19)
M10713 (hSBA ≥1:8) (6months) (N= 104)52 (42 to 62)
SecondaryPercentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains. Analysis was done on MITT population (Secondary).

Time frame:
1 month post two catch-up doses versus prevaccination
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
Percentage of subjectsB_24_26
H44/76-SL (N=105)100 (97 to 100)
5/99 (N= 101)99 (95 to 100)
NZ98/254 (N=108 )96 (91 to 99)
M10713 (N= 99)85 (76 to 91)
SecondaryGMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.

To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain. Analysis was done on MITT population (Secondary).

Time frame:
1 month and 6 months post two catch-up doses.
Reported as:
Geometric mean · Concentration IU/mL
GMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.
Concentration IU/mLB_24_26
287-953 strain (1months)5448 (4630 to 6411)
287-953 strain (6months)383 (319 to 459)
SecondaryNumber of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.

To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.

Time frame:
Up to 7 days after any vaccination.
Reported as:
Number · Number of subjects
Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.
Number of subjectsB13_15_27B12_14_26
Any Local6416
Tenderness (N=67,17)6316
Erythema (N=)4713
Induration379
Swelling359
Any Systemic5315
Change Eat. Habits (N=67,17)259
Sleepiness227
Vomiting40
Diarrhea41
Irritability4014
Unusual Crying165
Rash10
Fever ( >= 38C )226
Temperature (>= 40 C)00
Medical Attend. Fever00
Antipyr. Med. Used Prev5512
Antipyr. Med. Used Trt4711
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.

To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.

Time frame:
Up to 7 days after any vaccination.
Reported as:
Number · Number of Subjects
Number of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.
Number of SubjectsB13_15_27B12_14_26
Any AE4510
SAEs21
At least possibly related SAEs00
AEs leading to withdrawal00
SecondaryNumber of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.

Time frame:
Up to 7 days after any vaccination.
Reported as:
Number · Number of subjects
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
Number of subjectsB_24_26
Any Local110
Tenderness109
Erythema103
Induration75
Swelling58
Any Systemic98
Change Eat. Habits53
Sleepiness70
Vomiting14
Diarrhea23
Irritability84
Unusual Crying47
Rash14
Fever ( >= 38C)44
Temperature (>= 40 C)1
Medical Attend. Fever2
Antipyr. Med. Used Prev33
Antipyr. Med. Used Trt38
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.

To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.

Time frame:
Up to 7 days after any vaccination
Reported as:
Number · Number of Subjects
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.
Number of SubjectsB_24_26
Any AE96
Serious AEs6
At least possibly related SAEs0
AEs leading to withdrawal1

Adverse events

Collected over Throughout the study (solicited and unsolicited from Day 1 to Day 209). Any solicited and unsolicited adverse events, unsolicited SAE, medically attended AEs, AEs leading to withdrawal from the study were collected from day 1 through day.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B13_15_27—2/67 (3%)67/67 (100%)
B12_14_26—1/18 (5.6%)18/18 (100%)
B24_26—6/112 (5.4%)110/112 (98.2%)
Most frequent serious events
Most frequent serious events
EventB13_15_27B12_14_26B24_26
Oral HerpesInfections and infestations0/671/180/112
BronchitisInfections and infestations1/670/181/112
LaryngitisInfections and infestations1/670/180/112
CholesteatomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/670/181/112
Adenoidal HypertrophyNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/670/181/112
EnteritisGastrointestinal disorders0/670/181/112
Metabolism and nutrition disordersMetabolism and nutrition disorders0/670/181/112
Otitis MediaInfections and infestations0/670/181/112
Pneumonia Respiratory SyncytialInfections and infestations0/670/181/112
Most frequent other events
Showing 10 of 28
Most frequent other events
EventB13_15_27B12_14_26B24_26
Injection Site PainGeneral disorders63/6716/18109/112
Injection Site ErythemaGeneral disorders47/6713/18103/112
IrritabilityPsychiatric disorders40/6714/1884/112
SomnolenceNeoplasms benign, malignant and unspecified (incl cysts and polyps)22/677/1870/112
Injection Site SwellingGeneral disorders35/679/1858/112
Eating DisorderPsychiatric disorders25/679/1853/112
CryingGeneral disorders16/675/1847/112
PyrexiaGeneral disorders22/676/1846/112
DiarrhoeaGastrointestinal disorders5/671/1824/112
Upper Respiratory Tract InfectionInfections and infestations5/671/1820/112

Baseline characteristics

Age, Continuous
Age, Continuous(months)B246_12M12B246_12M13B13_15_27B12_14_26B_24_26B12M13Total
Mean25 ± 1.025.3 ± 0.927.3 ± 0.926.6 ± 1.224.7 ± 1.426 ± 025.4 ± 1.3
Sex: Female, Male
Sex: Female, Male(Participants)B246_12M12B246_12M13B13_15_27B12_14_26B_24_26B12M13Total
Female8768379610262
Male65853010551246
Region of Enrollment
Region of Enrollment(Number of Subjects)B246_12M12B246_12M13B13_15_27B12_14_26B_24_26B12M13Total
Czech Republic1051134714660345
Finland4740205501163
08

Study locations

19 sites
  • amostatná ordinace praktického lékaře pro děti a dorost Jindřichův Hradec
    Hradec, Czech Republic
  • Dětské oddělení nemocnice Náchod
    Náchod, Czech Republic
  • Dětské oddělení nemocnice Pardubice
    Pardubice, Czech Republic
  • University of Tampere Medical School, Vaccine Research Center Tampere
    Biokatu 10, Tampere 33520, Finland
  • Espoo Vaccine Research Clinic,
    Espoo, Finland
  • Helsinki East, Vaccine Research Clinic,
    Helsinki, Finland
  • Helsinki South, Vaccine Research Clinic,
    Helsinki, Finland
  • Järvenpää, Vaccine Research Clinic
    Järvenpää, Finland
  • Kokkola Vaccine Research Clinic
    Kokkola, Finland
  • Kotka Vaccine Research Clinic
    Kotka, Finland
  • Kuopio Vaccine Research Clinic
    Kuopio, Finland
  • Lahti Vaccine Research Clinic
    Lahti, Finland
  • Oulu Vaccine Research Clinic
    Oulu, Finland
  • Pori Vaccine Research Clinic
    Pori, Finland
  • Seinäjoki Vaccine Research Clinic
    Seinäjoki, Finland
  • Tampere Vaccine Research Clinic
    Tampere, Finland
  • Turku Vaccine Research Clinic
    Turku, Finland
  • Vantaa East, Vaccine Research Clinic
    Vantaa, Finland
  • Vantaa West, Vaccine Research Clinic
    Vantaa, Finland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2010
First posted
Jun 8, 2010
Start
Jun 2010
Primary completionActual
Nov 2010
CompletionActual
Sep 2011
Results first posted
Apr 10, 2015
Last update
Apr 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01139021
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Jun 8, 2010
Start date
Jun 2010
Primary completion
Nov 2010
Completion
Sep 2011
Results posted
Apr 10, 2015
Last update
Apr 10, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion